Beta
Trial Radar KI
Die klinische Studie NCT07260864 (rTMS) für Fibromyalgia (FM) ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen.
Eine Studie entspricht den Filterkriterien
Kartenansicht

Investigating the Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on the Brain in People With Fibromyalgia 20

Noch nicht rekrutierend
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07260864 (rTMS) ist eine interventionsstudie zur Untersuchung von Fibromyalgia (FM) und hat den Status noch nicht rekrutierend. Der Start ist für 30. Dezember 2025 geplant, bis 20 Teilnehmer aufgenommen werden. Durchgeführt von Universität Rochester wird der Abschluss für 30. September 2026 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 3. Dezember 2025 aktualisiert.
Kurzbeschreibung
The first goal of this study is to see how brain activity changes in people with fibromyalgia after they get a treatment called rTMS (repetitive transcranial magnetic stimulation). Researchers are looking at how the parts of the brain that control movement (called motor cortices) respond to this treatment.

The second goal is to find out if the changes in brain activity are different between the right and left sides ...

Mehr anzeigen
Ausführliche Beschreibung
The first aim of this study is to measure changes in fibromyalgia-related functional brain plasticity, as indicated by the functional "connectopy" of the right and left primary motor cortices in response to rTMS treatment. The second aim of this study is to explore whether changes in motor cortex connectopy differ between the right and left motor cortex (M1) following rTMS administered to each respective hemisphere.
Offizieller Titel

Investigating the Differential Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Left and Right Motor Cortex in Fibromyalgia: A Prospective Randomized Trial With Functional Magnetic Resonance Imaging (MRI(

Erkrankungen
Fibromyalgia (FM)
Weitere Studien-IDs
  • rTMS
  • STUDY0000010795
  • Schmitt program (Andere Zuwendungs-/Finanzierungsnummer) (URMC)
NCT-Nummer
Studienbeginn (tatsächlich)
2025-12-30
Zuletzt aktualisiert
2025-12-03
Studienende (vorauss.)
2026-09-30
Geplante Rekrutierung
20
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Noch nicht rekrutierend
Stichwörter
Transcranial Magnetic Stimulation
Chronic Pain
Nociplastic pain
Functional Magnetic Resonance Imaging
Motor Cortex
Primäres Ziel
Andere
Zuteilungsmethode
Randomisiert
Interventionsmodell
Parallel
Verblindung
Doppelt verblindet
Studienarme/Interventionen
Teilnehmergruppe/StudienarmIntervention/Behandlung
Aktives Vergleichspräparatright M1 rTMS
rTMS
Using rTMS, which is a procedure that uses magnetic fields to stimulate nerve cells in the brain, to investigate its potential analgesic effects in fibromyalgia.
Aktives VergleichspräparatLeft M1 rTMS
rTMS
Using rTMS, which is a procedure that uses magnetic fields to stimulate nerve cells in the brain, to investigate its potential analgesic effects in fibromyalgia.
Hauptergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Mean Change in Primary Motor Cortex (M1) Connectopy Profile
Resting-state fMRI will be used to derive connectopy embeddings of the primary motor cortex (M1). Connectopy embeddings from the stimulated side will be extracted from significant baseline-defined clusters. A single value per participant is derived by averaging the embedding values within this cluster. Higher scores indicate increased similarity to healthy reference profiles (improved functional connectivity), while lower scores indicate deviation from healthy reference patterns (reduced functional connectivity).
Baseline and post-treatment (after 10 sessions of rTMS over 2 weeks).
Nebenergebnismessungen
ErgebnismessungBeschreibung der MessungZeitrahmen
Mean Change in Pain Intensity (Numeric Rating Scale, NRS)
Self-reported average pain over 7 days using the Numeric Rating Scale (0 = "no pain at all" to 10 = "worst pain possible"). A single number is derived as the mean of daily ratings over 7 days. Lower scores indicate reduced pain intensity, while higher scores indicate worse pain intensity.
Baseline and post-treatment (following 10 rTMS sessions, within 7 days of completing rTMS sessions ).
Mean Change in Pressure Pain Threshold (PPT)
Pressure pain threshold (PPT) will be measured using a pressure algometer (Wagner Inc.). Pressure will be applied at a constant rate until participants indicate pain perception. The threshold (kg/cm²) will be recorded. A single value is derived by averaging three threshold readings from the target site. Higher thresholds indicate reduced pain sensitivity (improvement), while lower thresholds indicate increased pain sensitivity (worsening).
Baseline and post-treatment (within 7 days of completing rTMS sessions )
Mean Change in Fatigue (Patient-Reported Outcomes Measurement Information System-PROMIS Fatigue 13a Subscale)
Fatigue will be assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue 13a subscale, which ranges from 13 to 65. Higher scores indicate greater fatigue severity (worsening), whereas lower scores indicate less fatigue (improvement).
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Sleep Disturbance (Patient-Reported Outcomes Measurement Information System - PROMIS Sleep Disturbance 8a Subscale)
Sleep disturbance will be assessed using the PROMIS (Patient-Reported Outcomes Measurement Information System) Sleep Disturbance 8a subscale, which ranges from 8 to 40. Higher scores indicate greater sleep disturbance (worsening), whereas lower scores indicate improved sleep.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in the Short-Form McGill Pain Questionnaire
The Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) has 22 items assessing continuous, intermittent, neuropathic, and affective pain. Items are rated 0-10, with total scores ranging 0-220, where higher scores indicate greater pain severity.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Central Sensitization Index
Central Sensitization Index (CSI) is a 25-item self-reported measure that determines whether the symptoms of patients are associated with central sensitization. Item responses are on a 4-point scale and can be answered as follows: 0 = Never, 1 = Rarely, 2 = Sometimes, 3 = Often, and 4 = Always. The total score will be used to estimate the severity of the central sensitization symptoms.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Pain Catastrophizing Scale
The Pain Catastrophizing Scale (PCS) has 13 items measuring rumination, magnification, and helplessness related to pain. Items are rated 0-4, with total scores ranging 0-52; higher scores indicate greater catastrophizing.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in the Pain Self-repot Survey for the Assessment of Fibromyalgia
The Patient Self-Report Survey for the Assessment of Fibromyalgia has 9 items measuring widespread pain and symptom severity. Scores range 0-31, with higher scores indicating greater fibromyalgia symptom burden.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Revised Fibromyalgia Impact Questionnaire
The Revised Fibromyalgia Impact Questionnaire (FIQR) is a 21-item, three-domain, self-reported measure of the impact of fibromyalgia on life. All questions include a 0-10 scale, and different domains have different calculations (function domain divided by 3, overall impact domain divided by 1, symptom domain divided by 2) before summing all scores. The total score will be used to estimate the changes in quality of life with interventions.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) measures sleep quality over the past month and consists of seven components assessing various aspects of sleep quality and sleep-related daytime functioning. The index will be used to estimate the overall sleep quality of participants, with total scores ranging from 0 to 21, where higher scores indicate worse sleep quality.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Chronic Overlapping Pain Conditions Screener
Chronic Overlapping Pain Conditions Screener (COPCS) is a self-report tool that uses a body map and trigger questions to screen for 10 chronic overlapping pain conditions and outputs the number of conditions present (0-10).
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Hospital Anxiety and Depression Scale
The Hospital Anxiety and Depression Scale (HADS) has 14 items, 7 each for anxiety and depression. Each item is rated 0-3, with subscale scores ranging 0-21; higher scores indicate greater symptom severity.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Beck Depression Inventory
The Beck Depression Inventory (BDI) has 21 items assessing depressive symptoms. Each item is rated 0-3, with total scores ranging 0-63; higher scores indicate greater depression severity.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Mean Change in Beck Anxiety Inventory
The Beck Anxiety Inventory (BAI) has 21 items assessing anxiety symptoms. Each item is rated 0-3, with total scores ranging 0-63; higher scores indicate greater anxiety severity.
Baseline and post-treatment (within 7 days of completing rTMS sessions).
Teilnahme-Assistent
Eignungskriterien

Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Weiblich
  • Female aged 18 to 65, right-handed, with no racial/ethnic restrictions.
  • A diagnosis of fibromyalgia by a qualified physician according to the American College of Rheumatology 2016 criteria
  • Must have a history of fibromyalgia pain for a duration ≥ 3 months, as it is included in the diagnostic criteria.
  • Must have pain intensity equal or greater than 4/10 on the numerical rating scale (NRS) at enrollment.
  • Concurrent chronic overlapping pain conditions (except migraine with aura), depression, and anxiety will be allowed when mild to moderate (Less than 31 on Beck Depression Inventory or less than 36 on Beck Anxiety Inventory), except in cases with psychotic or manic features.
  • Concomitant medication (except tricyclics, antipsychotic medications, bupropion, methadone, theophylline) and their doses for mood, pain and sleep disorders must be steady at least 4 weeks before enrolment and must be kept at a steady dosage during the trial.
  • Must be able to read and speak English and be willing to read and understand instructions as well as questionnaires.
  • Must be in generally stable health.
  • Must sign an informed consent document after explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate.

  • Inability to provide informed consent.
  • Age outside the studied range (i.e., < 18, > 65).
  • Patients planning to change their medications during trial.
  • Participants who are currently receiving other alternative therapies during trial (e.g., physiotherapy, acupuncture).
  • History of receiving TMS, transcranial direct current stimulation (tDCS), or electroconvulsive therapy (ECT).
  • Evidence of rheumatologic disorders, autoimmune diseases, taking immunosuppressive treatment, severe or unstable cardiac diseases.
  • Fibromyalgia must be the primary complaint; hence patients cannot have another main source of pain (e.g., osteoarthritis). Patients will be asked to shade all the areas in which they experience pain on a body map. If they shade areas other than typical fibromyalgia pain, we will discuss any previous diagnosis, the intensity and chronicity of pain, and exclude them if chronic pain in any area outside the condition in to be studied is confirmed.
  • Involvement in litigation regarding their pain or having a disability claim or receiving workman compensation or seeking either because of their pain.
  • Any history of hemorrhagic or thrombotic stroke.
  • History of schizophrenia, schizoaffective disorder, bipolar disorders, mania, hypomania, eating disorders, or any psychiatric illness with psychotic features (major depressive disorder, mild to moderate without psychosis, or anxiety disorders are not exclusion criteria).
  • Current use of tricyclic antidepressants or any antipsychotic medications, given the risk of seizure incidence independent of TMS use in tricyclics is up to 0.4% or second-generation antipsychotics up to 1.2%.
  • Significant other medical disease such as unstable diabetes mellitus, congestive heart failure, coronary or peripheral vascular disease, chronic obstructive lung disease, sleep apnea, or malignancy. Stable diabetes mellitus, stable hypertension (meaning that these conditions are followed up on by a physician and they are getting treatment for it with clinical stability), or hyperlipidemia are not exclusion criteria.
  • History of traumatic brain injury
  • History of epileptic disorders or family history of seizures in first degree relatives
  • History of syncope
  • History of tinnitus or hearing loss
  • Current or history of substance misuse/dependence including alcohol at time of entry into the study.
  • History of COVID-19 infection with persistent neurologic symptoms.
  • Intra-axial implants (e.g., spinal cord stimulators or pumps) that are MRI incompatible.
  • All exclusion criteria for MRI and TMS safety: any metallic implants, chips, or plates, cochlear implants, brain or skull abnormalities, aneurysm clips or coils, non-removable piercings, tattoos containing ferromagnetic ink, and claustrophobia.
  • Surgery within the past 3 months or history of any brain surgery
  • Pregnancy
  • Participation into another research study
  • In the judgment of the investigator, unable or unwilling to follow the protocol and instructions.
Verantwortliche Partei
Paul Geha, Hauptprüfer, Associate Professor of psychiatry, University of Rochester
Zentrale Studienkontakte
Kontakt: Olivia Caraccio, BS/BA, 5853136322, [email protected]
1 Studienstandorte in 1 Ländern

New York

University of Rochester Medical Center, Rochester, New York, 14620, United States
Olivia Caraccio, BS, Kontakt, 5853136322, [email protected]